CEA belongs to a type of carcinoembryonic antigen, which is a glycoprotein. During fetal life, the fetal gastrointestinal tract, liver and pancreas have the ability to synthesize carcinoembryonic antigen, while after birth, the plasma level of carcinoembryonic antigen will be low. There are many kinds of gynecological tumors, such as cervical cancer, endometrial cancer, ovarian epithelial cancer, vaginal cancer, and even in female vulvar cancer can be detected with positive CEA expression. Therefore, CEA does not have a specific marker function for the type of tumor. Among gynecologic malignancies, mucinous adenocarcinoma of the ovary has the highest CEA positivity rate; followed by endometrioid carcinoma and clear cell carcinoma, which also have a significant level of CEA expression; while tumors of the plasma will have a relatively low positivity rate. For example, the CEA positivity rate for mucinous benign tumors of the ovary is about 15%, for junctional tumors it is about 80%, and for malignant tumors it is almost 100%. 50% of ovarian cancer patients also have slightly elevated serum CEA levels, especially for mucinous hypofractionated carcinomas. The survival time is relatively short when the CEA level in the serum is consistently elevated or is able to express the presence of recurrent malignant tumors, ovarian tumors. Therefore, with the help of CEA measurement, it is of good landmark clinical value to dynamically monitor or track the changes in the condition of gynecologic tumor patients, observe the next step of treatment, treatment effect, develop treatment plan, etc.